1. Home
  2. CNTX vs BTCS Comparison

CNTX vs BTCS Comparison

Compare CNTX & BTCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Context Therapeutics Inc.

CNTX

Context Therapeutics Inc.

N/A

Current Price

$0.17

Market Cap

47.7M

Sector

Health Care

ML Signal

N/A

Logo BTCS Inc.

BTCS

BTCS Inc.

N/A

Current Price

$0.75

Market Cap

52.8M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CNTX
BTCS
Founded
2015
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
47.7M
52.8M
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
CNTX
BTCS
Price
$0.17
$0.75
Analyst Decision
Buy
Analyst Count
10
0
Target Price
★ $3.79
N/A
AVG Volume (30 Days)
★ 1.2M
651.3K
Earning Date
11-10-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 17.39
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $16,491,584.00
Revenue This Year
N/A
$21.27
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 304.85
52 Week Low
$0.15
$0.76
52 Week High
$3.62
$3.63

Technical Indicators

Market Signals
Indicator
CNTX
BTCS
Relative Strength Index (RSI) 36.02 28.42
Support Level N/A N/A
Resistance Level $0.22 $1.09
Average True Range (ATR) 0.02 0.08
MACD 0.00 -0.01
Stochastic Oscillator 33.07 5.69

Price Performance

Historical Comparison
CNTX
BTCS

About CNTX Context Therapeutics Inc.

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

About BTCS BTCS Inc.

BTCS Inc. ("BTCS" or the "Company"), short for Blockchain Technology Consensus Solutions, is a U.S.-based Ethereum-first blockchain technology company committed to driving scalable revenue and ETH accumulation through its hallmark strategy, the DeFi/TradFi Accretion Flywheel, an integrated approach to capital formation and blockchain infrastructure. By combining decentralized finance ("DeFi") and traditional finance ("TradFi") mechanisms with its blockchain infrastructure operations, comprising NodeOps (staking) and Builder+ (block building), BTCS offers one of the most sophisticated opportunities for leveraged ETH exposure, driven by scalable revenue generation and a yield-focused ETH accumulation strategy. Discover how BTCS offers operational and financial leveraged exposure to Ethereum through the public markets at www.btcs.com.

Share on Social Networks: